Adverum Biotechnologies Inc Stock price
Is Adverum Biotechnologies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.
Key metrics
Adverum Biotechnologies Inc Stock Analysis
Analyst Opinions
12 Analysts have issued a Adverum Biotechnologies Inc forecast:
Analyst Opinions
12 Analysts have issued a Adverum Biotechnologies Inc forecast:
Don't miss a Thing! We will send you all news about Adverum Biotechnologies Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
| Head office | United States |
| CEO | Dr. Fischer |
| Employees | 155 |
| Founded | 2006 |
| Website | adverum.com |


